omniture
CARSGEN THERAPEUTICS CO LTD

Latest News

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma

SHANGHAI, April 27, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharma...

2020-04-27 18:00 758

CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs

SHANGHAI, Jan 6, 2020 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to d...

2020-01-06 18:00 519

CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody

SHANGHAI, Dec. 9, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage biopharmaceutical com...

2019-12-09 18:00 387

CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency

SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceuti...

2019-09-23 18:00 2347

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA

SHANGHAI, June 19, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to...

2019-06-19 18:00 2686

CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA

SHANGHAI, March 1, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to...

2019-03-01 18:00 1326

CARsgen Therapeutics Receives IND Clearance for GPC3-CAR-T Cells from the NMPA

SHANGHAI, Jan. 29, 2019 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to...

2019-01-29 18:00 836

CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018

SHANGHAI, Dec. 4, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to ...

2018-12-04 20:00 724

CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development

SHANGHAI, Aug. 27, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to...

2018-08-27 21:00 854

CARsgen Completed $60 Million Pre-C Financing Framework Agreements

SHANGHAI, March 2, 2018 /PRNewswire/ -- CARsgen Therapeutics, a leading immune-oncology company foc...

2018-03-02 14:00 1734

CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial

SHANGHAI, Aug. 10, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global leader in developi...

2017-08-10 14:10 1323

CARsgen Therapeutics Joins The Alliance for Regenerative Medicine

SAN DIEGO, Calif., June 30, 2017 /PRNewswire/ --CARsgen Therapeutics (CARsgen), a global pioneer ...

2017-06-30 19:57 2143

CARsgen Therapeutics Presented at the 2017 BIO International Convention

SAN DIEGO, June 23, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global biotech start-up ...

2017-06-23 12:00 2596

CARsgen Presents Phase I Results of CAR-GPC3 T HCC Trial at ASCO 2017 Annual Meeting

CHICAGO, June 5, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global biotech start-up foc...

2017-06-05 14:30 1898

CARsgen Therapeutics Opens CAR T-cell Manufacturing Facility in Shanghai

SHANGHAI, May 3, 2017 /PRNewswire/ -- CARsgen Therapeutics (CARsgen), a global leader in developing...

2017-05-03 19:15 2176

CARsgen Therapeutics Completes $30 Million Series B Financing

SHANGHAI, Jan. 25, 2016 /PRNewswire/ -- CARsgen Therapeutics, a private and venture backed company f...

2016-01-25 23:00 2088

CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology

SHANGHAI, Sept. 29, 2015 /PRNewswire/ -- CARsgen Therapeutics, a private and venture backed company ...

2015-09-29 22:00 2079